Insider Selling: BioMarin Pharmaceutical Inc. (BMRN) EVP Sells 1,200 Shares of Stock
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP George Eric Davis sold 1,200 shares of the company’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $85.64, for a total value of $102,768.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded down $1.38 during trading hours on Monday, hitting $83.62. The stock had a trading volume of 736,595 shares, compared to its average volume of 1,225,378. The company has a current ratio of 4.91, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41. BioMarin Pharmaceutical Inc. has a twelve month low of $79.50 and a twelve month high of $100.51.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The business had revenue of $334.18 million for the quarter, compared to the consensus estimate of $347.38 million. During the same period in the prior year, the business earned $0.02 earnings per share. The business’s revenue was up 19.4% on a year-over-year basis. equities analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.65 EPS for the current fiscal year.
A number of research analysts recently weighed in on BMRN shares. Zacks Investment Research lowered BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Piper Jaffray Companies started coverage on BioMarin Pharmaceutical in a report on Thursday, September 14th. They set an “overweight” rating and a $113.00 price objective on the stock. Citigroup started coverage on BioMarin Pharmaceutical in a report on Thursday, August 31st. They set a “buy” rating and a $98.00 price objective on the stock. Royal Bank Of Canada started coverage on BioMarin Pharmaceutical in a research report on Thursday, September 14th. They set a “sector perform” rating and a $93.00 target price on the stock. Finally, Morgan Stanley reiterated an “overweight” rating and set a $117.00 target price (up from $115.00) on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have given a buy rating to the stock. BioMarin Pharmaceutical presently has a consensus rating of “Hold” and an average price target of $111.59.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.